Carter's (CRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ECPG, UVE and CRI made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 2, 2026.
CZNC, UCB and CRI made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 2, 2026.
Carter's, Inc. (CRI) Q4 2025 Earnings Call Transcript
CRI tops Q4 estimates with 7.6% sales growth, but stock sinks over 15% on soft Q1 and 2026 earnings outlook.
Carter's, Inc. reported Q4 results with solid top-line growth but significant margin deterioration due to tariffs and higher costs. FY26 guidance projects modest revenue growth driven by pricing, but persistent gross margin pressure and higher interest expense will weigh on net income. CRI trades at 10x forward earnings, yet secular headwinds like declining fertility and inability to offset tariffs undermine the investment case.
Carter's (CRI) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $2.39 per share a year ago.
Here is how Carter's (CRI) and Dolby Laboratories (DLB) have performed compared to their sector so far this year.
CRI posts high single-digit Q4 sales growth, driven by U.S. Retail and e-commerce gains, even as inflation and rising SG&A costs pressure margins.
Carter's (CRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Consumer discretionary enters earnings season with brand-driven demand, digital momentum and easing costs, even as macro volatility and cautious spending linger.